Phase Ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets

Oncologist

Volumn 19, Issue 4, 2014, Pages 344-345

  Toffalorio, Francesca ^a   Spitaleri, Gianluca ^a   Catania, Chiara ^a   Zotto, Laura Dal ^b   Noberasco, Cristina ^a   Delmonte, Angelo ^a   Santarpia, Mariacarmela ^a   Vecchio, Fabio ^a   Brunelli, Veronica ^a   Rampinelli, Cristiano ^a   Barberis, Massimo ^a   Fumagalli, Caterina ^a   Zucchetti, Massimo ^c   Zangarini, Monique ^c   Diena, Tullia ^b   Danesi, Romano ^d   De Braud, Filippo ^e   De Pas, Tommaso ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b SENDO   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; RAPAMYCIN; RAS PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; NEOPLASMS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SIROLIMUS;

EID: 84898411259     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0335     Document Type: Article

References (0)